• Regulatory approval received for Registrational Phase 3 Clinical Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
• Ethics approval received to commence dosing in Indonesian Registrational Phase 3 Clinical Trial
• Patient dosing complete for Phase II ABSSSI Clinical Trial, data readouts expected Q1 CY25
• A$6.75m Research & Development rebate received
• Australia Patent Granted for RECCE® Anti-Infectives

Recce Pharmaceuticals Ltd has released its December 2024 quarter results and operational highlights. The company ended the quarter with a cash balance of A$1.94 million, with net cash outflows from operating activities of (A$2.67 million). The company received a A$6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2024. Regulatory approval was received from Indonesia's Drug and Food Authority for a Registrational Phase 3 clinical trial assessing RECCE® 327 as a topical gel (R327G) for the treatment of diabetic foot infections (DFIs). Ethics approval was also received to commence this trial. Patient dosing is now complete for the company's Phase II clinical trial of R327G in Acute Bacterial Skin and Skin Structure Infections (ABSSSI), with full results expected in Q1 2025. Additionally, the Australian Patent Office has granted Patent Family 3 for Recce's Anti-infectives through to 2037.

Following recent Phase III clinical trial approvals, the Company is focused on achieving key milestones, including the release of the Phase II ABSSSI clinical data report and the commencement of the Phase III DFI clinical trial in Indonesia. Recce is well-positioned to deliver on its operational and clinical goals in the coming quarter.